HLS Therapeutics (TSE:HLS) Reaches New 12-Month Low – What’s Next?

Shares of HLS Therapeutics Inc. (TSE:HLS) reached a new 52-week low during trading on Friday. The stock traded as low as C$3.51 and last traded at C$3.65, with a volume of 78,476 shares. The stock had previously closed at C$3.70.

Analyst Upgrades and Downgrades

HLS has been the subject of several recent research reports. Raymond James Financial raised shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price target for the stock from C$7.00 to C$8.00 in a research note on Friday, August 14th. Canaccord Genuity Group upgraded shares of HLS Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Strong Buy” and a consensus target price of C$8.00.

HLS Therapeutics Stock Up 0.3%

The firm has a market cap of C$114.77 million, a PE ratio of -13.74 and a beta of -0.52. The company has a debt-to-equity ratio of 80.62, a quick ratio of 1.01 and a current ratio of 1.05. The company’s 50-day simple moving average is C$4.11 and its two-hundred day simple moving average is C$4.29.

HLS Therapeutics (TSE:HLS) last announced its quarterly earnings results on Thursday, November 12th. The company reported C($0.10) EPS for the quarter. HLS Therapeutics had a negative return on equity of 12.14% and a negative net margin of 12.10%. The business had revenue of C$20.15 million during the quarter. On average, analysts predict that HLS Therapeutics Inc. will post -0.12 earnings per share for the current fiscal year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.